A summary of the CHMP meeting conclusions, including medicines recommended for approval and indication extension and several safety review findings.
List view / Grid view
Filter the results
A study conducted in the US has revealed that the majority of medical marijuana dispensed in the US has THC levels of up to 15 percent.
A Phase Ib trial for the study of the oral formulation for Amphotericin B has met its primary endpoints, demonstrating safety in patients.
Hospitalised patients in the UK will inhale the interferon beta 1a (IFN-β) formulation or a placebo to see if SNG001 is effective against the COVID-19 coronavirus.
Developers have announced that they are ready to manufacture and formulate an innovative novel coronavirus vaccine capsule.
The EMA has announced the results of its pharmacovigilance meeting for March, saying that it has started a review of medicines containing ifosfamide due to a higher risk of encephalopathy.
Researchers have created an innovative 3D printing carrier ink to drive the development of personalised biomaterials for cell and drug delivery.
The US FDA has granted Fast Track designation to Jardiance® for the treatment of chronic kidney disease.
The regulatory body has issued guidance based on a complaint that stated a precipitate formed in Aripiprazole 1mg/ml oral solution.
Novel particles could be incorporated into topical creams to treat dermatological conditions without systemic exposure to drugs.
US researchers have stated a newly approved HIV pre-exposure prophylaxis (PrEP) therapy does not have benefits that warrant its price tag and could deter generic competition.
Development of a new method to create chiral rotaxanes has allowed researchers to show they could be ideal environments for catalysts.
Using AAV-based technology to deliver mAbs in a Phase I trial, researchers report that participants successfully developed antibodies against HIV.
Researchers have identified a tiny protein in scorpion venom that rapidly accumulates in joint cartilage to deliver arthritis drugs in a pre-clinical study.
Tests conducted by an online pharmacy has revealed high levels of NMDA in the diabetes drug metformin, prompting the company to press for a recall.